[go: up one dir, main page]

DK1017814T3 - Anticaliner - Google Patents

Anticaliner

Info

Publication number
DK1017814T3
DK1017814T3 DK98954239T DK98954239T DK1017814T3 DK 1017814 T3 DK1017814 T3 DK 1017814T3 DK 98954239 T DK98954239 T DK 98954239T DK 98954239 T DK98954239 T DK 98954239T DK 1017814 T3 DK1017814 T3 DK 1017814T3
Authority
DK
Denmark
Prior art keywords
anticalins
leaflet
polypeptides
mutation
bind
Prior art date
Application number
DK98954239T
Other languages
English (en)
Inventor
Arne Skerra
Gerald Beste
Frank Schmidt
Thomas Stibora
Original Assignee
Pieris Proteolab Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pieris Proteolab Ag filed Critical Pieris Proteolab Ag
Application granted granted Critical
Publication of DK1017814T3 publication Critical patent/DK1017814T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Insects & Arthropods (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK98954239T 1997-09-26 1998-09-25 Anticaliner DK1017814T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19742706A DE19742706B4 (de) 1997-09-26 1997-09-26 Lipocalinmuteine
PCT/DE1998/002898 WO1999016873A1 (de) 1997-09-26 1998-09-25 Anticaline

Publications (1)

Publication Number Publication Date
DK1017814T3 true DK1017814T3 (da) 2003-02-17

Family

ID=7843826

Family Applications (2)

Application Number Title Priority Date Filing Date
DK98954239T DK1017814T3 (da) 1997-09-26 1998-09-25 Anticaliner
DK02020399.8T DK1270725T3 (da) 1997-09-26 1998-09-25 Anticaliner

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK02020399.8T DK1270725T3 (da) 1997-09-26 1998-09-25 Anticaliner

Country Status (7)

Country Link
US (4) US7250297B1 (da)
EP (2) EP1270725B1 (da)
AT (2) ATE226248T1 (da)
AU (1) AU1143799A (da)
DE (3) DE19742706B4 (da)
DK (2) DK1017814T3 (da)
WO (1) WO1999016873A1 (da)

Families Citing this family (420)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9903584D0 (en) * 1999-02-18 1999-04-07 Univ Leeds Modified calycins
DE19926068C1 (de) * 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
US6114123A (en) * 1999-06-14 2000-09-05 Incyte Pharmaceuticals, Inc. Lipocalin family protein
DE19932688B4 (de) * 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
GB0020749D0 (en) * 2000-08-24 2000-10-11 Univ Leeds Calycins
CA2464690A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
WO2003029462A1 (en) * 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
EP1318195A1 (en) * 2001-12-10 2003-06-11 CatchMabs B.V. A structure for presenting desired peptide sequences
WO2003099859A2 (de) 2002-05-27 2003-12-04 Per Sonne Holm Neue verwendung von adenoviren und dafür codierenden nukleinsäuren
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
ATE419865T1 (de) 2002-08-14 2009-01-15 Silence Therapeutics Ag Verwendung von protein-kinase-n-beta
EP1393742A1 (en) 2002-08-14 2004-03-03 atugen AG Use of protein kinase N beta
CA2502414A1 (en) 2002-10-15 2004-04-29 Intercell Ag Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof
US20060240022A1 (en) 2002-10-18 2006-10-26 Atugen Ag Factor involved in metastasis and uses thereof
EP1470824A1 (en) * 2002-12-10 2004-10-27 L-MAbs B.V. Affinity proteins for controlled application of cosmetic substances
EP2287311A1 (en) 2003-03-04 2011-02-23 Intercell AG Streptococcus pyogenes antigens
US7628994B2 (en) 2003-03-31 2009-12-08 Intercell Ag S. epidermidis antigens
US7635487B2 (en) 2003-04-15 2009-12-22 Intercell Ag S. pneumoniae antigens
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
AU2004235952A1 (en) 2003-05-07 2004-11-18 Intercell Ag Streptococcus agalactiae antigens I + II
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
EP2267006A1 (en) 2003-05-30 2010-12-29 Intercell AG Enterococcus antigens
AU2003264100A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of a bilin-binding protein with affinity for a given target
WO2005019255A1 (en) * 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
CA2546178A1 (en) 2003-11-14 2005-06-09 Per Sonne Holm New use of adenovirus and nucleic acids coding therefor
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
DE102004049479A1 (de) 2004-10-11 2006-04-13 Scil Proteins Gmbh Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
EP1814988A2 (en) 2004-11-26 2007-08-08 Pieris AG Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
US7749694B2 (en) 2004-12-31 2010-07-06 The Regents Of The University Of California C-type lectin fold as a scaffold for massive sequence variation
US7611847B2 (en) * 2005-06-01 2009-11-03 Agency For Science, Technology And Research Method for identifying an intestinal phenotype
ATE501169T1 (de) 2005-12-30 2011-03-15 Evonik Roehm Gmbh Lactoferrin-peptide, geeignet als in die zelle eindringende peptide
CN101371124B (zh) 2006-02-13 2012-02-29 新加坡科技研究局 处理生物样品和/或化学样品的方法
JP5823663B2 (ja) 2006-03-03 2015-11-25 プロミス ニューロサイエンシズ インコーポレイテッド ミスフォールドｓｏｄ１媒介疾患を処置および検出するための方法および組成物
EP1996613B1 (en) * 2006-03-20 2014-04-30 Technische Universität München Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4
ES2548392T3 (es) 2006-05-15 2015-10-16 Avidbiotics Corporation Bacteriocinas modificadas y métodos para su uso
US8445639B2 (en) 2006-05-15 2013-05-21 Avidbiotics Corporation Recombinant bacteriophage and methods for their use
US7700729B2 (en) 2006-05-15 2010-04-20 Avidbiotics Corporation Modified bacteriocins and methods for their use
WO2007134818A2 (en) 2006-05-18 2007-11-29 Univ Muenchen L Maximilians Method for diagnosing mitochondrial dysfunction
WO2007145579A1 (en) * 2006-06-16 2007-12-21 Biotech Igg Ab An adsorption device
EP2046375B1 (en) 2006-07-20 2017-04-05 The General Hospital Corporation Methods and compositions for the selective activation of protoxins through combinatorial targeting
US8232256B2 (en) 2006-07-21 2012-07-31 Silence Therapeutics Ag Means for inhibiting the expression of protein kinase 3
ES2354653T3 (es) * 2006-08-01 2011-03-16 Pieris Ag Muteínas de lipocalina lacrimal y procedimientos para obtener las mismas.
DE602007009995D1 (de) * 2006-08-01 2010-12-02 Pieris Ag Muteine von tearlipocalin und verfahren zu deren gewinnung
WO2008030611A2 (en) 2006-09-05 2008-03-13 Medarex, Inc. Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
EP2059526A2 (en) 2006-09-15 2009-05-20 Intercell AG Borrelia antigens
ES2625798T3 (es) 2006-10-02 2017-07-20 E. R. Squibb & Sons, L.L.C. Anticuerpos humanos que se unen a CXCR4 y usos de los mismos
EP1913955A1 (en) 2006-10-19 2008-04-23 Gerhard, Markus Novel method for treating H.pylori infections
EP1925664A1 (en) * 2006-11-15 2008-05-28 Scil proteins GmbH Artificial binding proteins based on a modified alpha helical region of ubiquitin
MX2009005466A (es) 2006-11-22 2009-08-17 Adnexus A Bristol Myers Sqibb Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas, incluyendo receptor de factor de crecimiento tipo insulina-i.
NZ578064A (en) 2006-12-01 2012-01-12 Medarex Inc Human antibodies that bind cd22 and uses thereof
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
WO2008074004A2 (en) 2006-12-14 2008-06-19 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
NZ579594A (en) 2007-03-12 2012-03-30 Esbatech Alcon Biomed Res Unit Sequence based engineering and optimization of single chain antibodies
EP2360177A1 (en) 2007-05-02 2011-08-24 Intercell AG Klebsiella antigens
EP2155238B1 (en) 2007-06-05 2016-04-06 Yale University Antibody against d4 domain of the kit receptor and use thereor
EP2511291A3 (en) 2007-06-18 2012-11-07 Intercell AG Chlamydia antigens
JP5611820B2 (ja) 2007-06-25 2014-10-22 エスバテック − ア ノバルティスカンパニー エルエルシー 抗体の修飾方法並びに改善された機能特性を有する修飾された抗体
JP5506670B2 (ja) 2007-06-25 2014-05-28 エスバテック − ア ノバルティス カンパニー エルエルシー 単鎖抗体の配列に基づくエンジニアリング及び最適化
CN104710518A (zh) * 2007-07-31 2015-06-17 阿菲博迪公司 新白蛋白结合组合物、方法及应用
EP2040075A1 (en) 2007-09-24 2009-03-25 Julius-Maximilians-Universität Würzburg Compounds and markers for surface-enhanced raman scattering
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
GB2453589A (en) 2007-10-12 2009-04-15 King S College London Protease inhibition
TW200944231A (en) 2007-11-30 2009-11-01 Glaxo Group Ltd Antigen-binding constructs
US8937047B2 (en) 2007-12-19 2015-01-20 General Electric Company Biokinetics of fast-clearing polypeptides
US8124725B2 (en) * 2007-12-19 2012-02-28 General Electric Company PDGF-Rβ binders
TW201012488A (en) 2008-05-06 2010-04-01 Glaxo Group Ltd Encapsulation of biologically active agents
CN102099373A (zh) 2008-05-22 2011-06-15 百时美施贵宝公司 基于纤连蛋白的多价支架结构域蛋白
EP2313430B1 (en) 2008-06-24 2018-05-02 Technische Universität München Muteins of hngal and related proteins with affinity for a given target
HUE056090T2 (hu) 2008-06-25 2022-01-28 Novartis Ag Immunkötõanyagok oldhatóságának optimalizálása
KR20110036638A (ko) 2008-07-25 2011-04-07 리차드 더블유. 와그너 단백질 스크리닝 방법
DK2328616T3 (da) 2008-08-05 2015-07-20 Novartis Ag Sammensætninger og fremgangsmåder for antistoffer mod komplementprotein C5
EP2323695B1 (en) 2008-08-19 2018-12-05 Nektar Therapeutics Complexes of small-interfering nucleic acids
FI20086073A0 (fi) * 2008-11-12 2008-11-12 Valtion Teknillinen Pienligandeihin sitoutuvat muunnetut avidiinit
ATE523603T1 (de) 2008-11-21 2011-09-15 Chimera Biotec Gmbh Konjugatkomplexe zum analytnachweis
JP5985826B2 (ja) 2008-12-16 2016-09-06 ノバルティス アーゲー 酵母ディスプレイ系
UY32341A (es) 2008-12-19 2010-07-30 Glaxo Group Ltd Proteínas de unión antígeno novedosas
CA2750581A1 (en) 2009-01-21 2010-07-29 Oxford Biotherapeutics Ltd. Pta089 protein
EP2405938A2 (en) 2009-02-13 2012-01-18 Intercell AG Nontypable haemophilus influenzae antigens
US20110305693A1 (en) 2009-02-24 2011-12-15 Glaxo Group Limited Anitigen-binding constructs
US20110305694A1 (en) 2009-02-24 2011-12-15 Paul Andrew Hamblin Multivalent and/or multispecific rankl-binding constructs
US20110305692A1 (en) 2009-02-24 2011-12-15 Glaxo Group Limited Antigen-binding contructs
BRPI1009232B1 (pt) 2009-03-05 2022-05-03 E.R. Squibb & Sons, Llc. Anticorpo monoclonal isolado ou uma porção de ligação de antígeno do mesmo, ou um fragmento de anticorpo, composição que os compreende, molécula de ácido nucleico, hibridoma e métodos para a preparação de um anticorpo anti-cadm1
EA030182B1 (ru) 2009-04-20 2018-07-31 Оксфорд Байотерепьютикс Лтд. Антитела, специфические для кадгерина-17
EA201101572A1 (ru) 2009-04-27 2012-05-30 Новартис Аг Композиции и способы применения терапевтических антител, специфичных в отношении субъединицы бета1 рецептора il-12
CA2993053A1 (en) 2009-04-27 2010-11-04 Novartis Ag Antagonistic activin receptor iib (actriib) antibodies for increasing muscle growth
IE20090514A1 (en) 2009-07-06 2011-02-16 Opsona Therapeutics Ltd Humanised antibodies and uses therof
SG177763A1 (en) 2009-07-28 2012-03-29 Hoffmann La Roche Non-invasive in vivo optical imaging method
BR112012002709A2 (pt) 2009-08-05 2019-04-30 Pieris Ag formulações de liberação controlada de muteínas de lipocalina
WO2011018421A1 (en) 2009-08-10 2011-02-17 Morphosys Ag Novel screening strategies for the identification of binders
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
EP2470569A1 (en) 2009-10-13 2012-07-04 Oxford Biotherapeutics Ltd. Antibodies against epha10
US20120282177A1 (en) 2009-11-02 2012-11-08 Christian Rohlff ROR1 as Therapeutic and Diagnostic Target
EP2496944A2 (en) 2009-11-05 2012-09-12 Novartis AG Biomarkers predictive of progression of fibrosis
CA2782814A1 (en) 2009-12-02 2011-06-09 Amgen Inc. Binding proteins that bind to human fgfr1c, human .beta.-klotho and both human fgfr1c and human .beta.-klotho
KR101974044B1 (ko) * 2009-12-07 2019-04-30 피어이스 파마슈티컬즈 게엠베하 주어진 표적에 대한 친화성을 갖는 인간의 리포칼린 2의 뮤테인
WO2011080050A2 (en) 2009-12-11 2011-07-07 Novartis Ag Binding molecules
WO2011073209A1 (en) 2009-12-14 2011-06-23 Scil Proteins Gmbh Modified ubiquitin proteins having a specific binding activity for the extradomain b of fibronectin
WO2011078794A1 (en) 2009-12-22 2011-06-30 Agency For Science, Technology And Research Sers-based analyte detection
MA34004B1 (fr) 2010-01-28 2013-02-01 Glaxo Group Ltd Protéines de liaison à cd127
BR112012019902A2 (pt) 2010-02-10 2019-09-24 Novartis Ag "método e compostos para o crescimento muscular"
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
NZ602634A (en) 2010-03-26 2015-06-26 Dartmouth College Vista regulatory t cell mediator protein, vista binding agents and use thereof
AU2011248625B2 (en) 2010-04-26 2017-01-05 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
CN103096911B (zh) 2010-04-27 2018-05-29 Atyr 医药公司 与异亮氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
US9034320B2 (en) 2010-04-29 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Valyl-tRNA synthetases
WO2011150279A2 (en) 2010-05-27 2011-12-01 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
US8986680B2 (en) 2010-04-29 2015-03-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
JP6008841B2 (ja) 2010-05-03 2016-10-19 エータイアー ファーマ， インコーポレイテッド メチオニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
JP6008840B2 (ja) 2010-05-03 2016-10-19 エータイアー ファーマ， インコーポレイテッド フェニルアラニルαｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
JP5976638B2 (ja) 2010-05-03 2016-08-23 エータイアー ファーマ， インコーポレイテッド アルギニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
EP2566499B1 (en) 2010-05-04 2017-01-25 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
SG185415A1 (en) 2010-05-06 2012-12-28 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
EP2566892B1 (en) 2010-05-06 2017-12-20 Novartis AG Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
EP2567234B1 (en) 2010-05-07 2018-09-19 F.Hoffmann-La Roche Ag Diagnostic method for the detection of cells ex vivo
EP2568996B1 (en) 2010-05-14 2017-10-04 aTyr Pharma, Inc. Therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
WO2011146410A2 (en) 2010-05-17 2011-11-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-trna synthetases
UY33421A (es) 2010-06-03 2011-12-30 Glaxo Wellcome House Proteinas de union al antígeno humanizados
ES2729652T3 (es) 2010-06-08 2019-11-05 Pieris Pharmaceuticals Gmbh Muteína de lipocalina lacrimal unidas a IL-4R alpha
HUE044419T2 (hu) 2010-07-09 2019-10-28 Bioverativ Therapeutics Inc Feldogozható egyetlen láncú molekulák és ezek alkalmazásával készült peptidek
WO2012021247A2 (en) 2010-07-12 2012-02-16 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
CA2808392C (en) 2010-08-16 2020-03-10 Pieris Ag Binding proteins for hepcidin
WO2012022496A2 (en) 2010-08-19 2012-02-23 Per Sonne Holm Method for killing tumor stem cells
ES2620255T3 (es) 2010-08-20 2017-06-28 Novartis Ag Anticuerpos para el receptor del factor de crecimiento epidérmico 3 (HER3)
EP2614073B1 (en) * 2010-09-07 2018-03-14 Technische Universität München Recombinant bacterial lipocalin blc and uses thereof
WO2012044992A2 (en) 2010-09-30 2012-04-05 Agency For Science, Technology And Research (A*Star) Methods and reagents for detection and treatment of esophageal metaplasia
CN103154037A (zh) 2010-10-05 2013-06-12 诺瓦提斯公司 抗IL12Rβ1抗体及它们在治疗自身免疫病和炎性疾病中的用途
DK2640740T3 (da) 2010-11-15 2017-06-26 Pieris Pharmaceuticals Gmbh Muteiner af human lipocalin 2 med affinitet til glypican-3 (gpc3)
PT2643352T (pt) 2010-11-23 2018-08-01 Glaxo Group Ltd Proteínas de ligação a antigénio para a oncostatina m (osm)
EP2643351A1 (en) 2010-11-24 2013-10-02 Glaxo Group Limited Multispecific antigen binding proteins targeting hgf
EP2646552B1 (en) 2010-12-02 2017-07-05 Pieris Pharmaceuticals GmbH Muteins of human lipocalin 2 with affinity for ctla-4
WO2012090150A2 (en) 2010-12-27 2012-07-05 Compugen Ltd New cell-penetrating peptides and uses thereof
WO2012136685A1 (en) 2011-04-04 2012-10-11 Pieris Ag Methods and compositions for anti-vegf and anti-c-met therapy
JP2014517685A (ja) 2011-04-15 2014-07-24 コンピュゲン エルティーディー． 免疫関連疾患およびがんの治療のためのポリペプチドおよびポリヌクレオチドならびにそれらの使用
GB201114858D0 (en) 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
SG194793A1 (en) 2011-05-06 2013-12-30 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
MY160884A (en) 2011-05-06 2017-03-31 Nexvet Australia Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
ES2905682T3 (es) 2011-05-06 2022-04-11 Zoetis Services Llc Anticuerpos anti-factor de crecimiento nervioso y métodos de preparación y uso de los mismos
CN103562225B (zh) 2011-05-27 2016-09-28 葛兰素集团有限公司 Bcma（cd269/tnfrsf17）结合蛋白
BR112013031943B1 (pt) 2011-06-13 2021-10-13 Csl Limited Composição que compreende proteínas e anticorpos contra g-csfr
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
WO2012171541A1 (en) 2011-06-15 2012-12-20 Scil Proteins Gmbh Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins
US9492572B2 (en) 2011-06-15 2016-11-15 Scil Proteins Gmbh Dimeric binding proteins based on modified ubiquitins
GEP201706667B (en) 2011-06-28 2017-05-25 Berlin - Chemie Ag Antibodies to adp-ribosyl cyclase 2
ME02632B (me) 2011-06-28 2017-06-20 Oxford Biotherapeutics Ltd Terapeutski i dijagnostički cilj
ES2692519T3 (es) 2011-07-01 2018-12-04 Novartis Ag Método para tratar trastornos metabólicos
JP2014526886A (ja) 2011-07-15 2014-10-09 モルフォシス・アー・ゲー マクロファージ遊走阻止因子（ｍｉｆ）とｄ−ドーパクロームトートメラーゼ（ｄ−ｄｔ）に交差反応性がある抗体
US9701749B2 (en) 2011-08-11 2017-07-11 Ono Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising PD-1 agonist
CN103906535B (zh) 2011-08-15 2017-07-14 芝加哥大学 与葡萄球菌蛋白a的抗体相关的组合物和方法
WO2013048986A1 (en) 2011-09-26 2013-04-04 Knoa Software, Inc. Method, system and program product for allocation and/or prioritization of electronic resources
CA2852709A1 (en) 2011-10-28 2013-05-02 Patrys Limited Pat-lm1 epitopes and methods for using same
US20130156766A1 (en) 2011-11-15 2013-06-20 Allergan, Inc. Treatment of dry age related macular degeneration
CN108341873B (zh) 2011-12-05 2022-03-25 诺华股份有限公司 表皮生长因子受体3(her3)的抗体
JP2015500829A (ja) 2011-12-05 2015-01-08 ノバルティス アーゲー 上皮細胞増殖因子受容体３（ｈｅｒ３）のドメインｉｉに対するｈｅｒ３の抗体
AU2012350654C1 (en) 2011-12-12 2018-05-10 Pieris Ag Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
SG10201604566QA (en) 2011-12-13 2016-07-28 Pieris Ag Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
EP2794656B1 (en) 2011-12-21 2019-02-27 Novartis AG Compositions comprising antibodies targeting factor p and c5
EP2802341B1 (en) 2012-01-09 2019-03-06 Pieris Pharmaceuticals GmbH Methods for preventing, treating or diagnosing disorders
JP6247226B2 (ja) 2012-01-10 2017-12-13 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 血液脳関門を越える治療分子の輸送の向上
US9758554B2 (en) 2012-01-31 2017-09-12 Technische Universitaet Muenchen Muteins of α1m lipocalin and method of production therefor
WO2013122544A2 (en) 2012-02-13 2013-08-22 Agency For Science, Technology And Research IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES
EP3311847A1 (en) 2012-02-16 2018-04-25 Atyr Pharma, Inc. Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US9701738B2 (en) 2012-04-26 2017-07-11 The University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during Staphylococcus aureus disease
CA2871160C (en) 2012-05-10 2023-03-14 Massachusetts Institute Of Technology Agents for influenza neutralization
US9133515B2 (en) 2012-05-16 2015-09-15 Silence Therapeutics Gmbh Use of VEGFR1 as a biomarker
EP2666775A1 (en) 2012-05-21 2013-11-27 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
US9522940B2 (en) 2012-05-23 2016-12-20 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
WO2013192504A1 (en) 2012-06-22 2013-12-27 The Trustees Of Dartmouth College Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
EP2882453B1 (en) 2012-08-07 2021-01-06 Massachusetts Institute of Technology Anti-dengue virus antibodies and uses thereof
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
CN109793893B (zh) 2012-09-07 2023-05-26 达特茅斯大学理事会 用于诊断和治疗癌症的vista调节剂
WO2014055836A2 (en) 2012-10-04 2014-04-10 Research Development Foundation Serine protease molecules and therapies
US9725512B2 (en) 2012-11-08 2017-08-08 Hoffmann-La Roche Inc. HER3 antibodies binding to the beta-hairpin of HER3
WO2014076321A1 (en) 2012-11-19 2014-05-22 Pieris Ag Novel specific-binding polypeptides and uses thereof
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
WO2014089111A1 (en) 2012-12-05 2014-06-12 Novartis Ag Compositions and methods for antibodies targeting epo
BR112015017338B1 (pt) 2013-02-08 2022-11-29 Novartis Ag Anticorpo humano terapêutico isolado ou sua porção de ligação ao antígeno do mesmo, seu uso e seu processo de produção, composição farmacêutica, molécula de ácido nucleico isolada, vetor de clonagem ou de expressão e micro-organismo transgênico
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
EP2962100B1 (en) 2013-02-28 2021-07-28 Caprion Proteomics Inc. Tuberculosis biomarkers and uses thereof
BR112015021681A2 (pt) 2013-03-14 2017-11-14 Daiichi Sankyo Co Ltd proteínas de ligação para pcsk9
EP3611189A1 (en) 2013-03-14 2020-02-19 Novartis AG Antibodies against notch 3
ES2935257T3 (es) 2013-03-15 2023-03-03 Univ Chicago Métodos y composiciones relacionadas con la actividad de las células T
RS59673B1 (sr) 2013-03-20 2020-01-31 Genzyme Corp Postupci za tretiranje osteogeneze imperfekta
US10526375B2 (en) 2013-06-05 2020-01-07 Massachusetts Institute Of Technology Human Adaptation of H7 HA
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
US9562101B2 (en) 2013-06-21 2017-02-07 Novartis Ag Lectin-like oxidized LDL receptor 1 antibodies and methods of use
WO2014210540A1 (en) 2013-06-28 2014-12-31 Baylor Research Institute Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
KR20160068738A (ko) 2013-08-14 2016-06-15 윌리엄 마쉬 라이스 유니버시티 운시알라마이신의 유도체, 합성 방법 및 항종양 제제로서 이들의 용도
AU2014307589A1 (en) 2013-08-14 2016-02-11 Novartis Ag Methods of treating sporadic inclusion body myositis
JP6584012B2 (ja) 2013-10-06 2019-10-02 アメリカ合衆国 改変シュードモナス外毒素ａ
JP2017502075A (ja) 2013-11-04 2017-01-19 ノクソン ファーマ エージー 腎障害治療の手段および方法
WO2015069459A1 (en) 2013-11-05 2015-05-14 Novartis Ag Organic compounds
DK3074038T3 (da) 2013-11-28 2019-03-11 Csl Ltd Fremgangsmåde til behandling af diabetisk nephropati
PL3082860T3 (pl) 2013-12-18 2021-06-14 Csl Limited Sposób leczenia ran
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
DK3087098T3 (da) 2013-12-24 2020-06-08 Janssen Pharmaceutica Nv Anti-Vista-antistoffer og -fragmenter
EP2894478B1 (en) * 2014-01-13 2017-01-11 Biomedical International R + D GmbH Method and means for diagnosing and treating allergy using lipocalin levels
WO2015104406A2 (en) 2014-01-13 2015-07-16 Pieris Ag Multi-specific polypeptide useful for localized tumor immunomodulation
US10286058B2 (en) 2014-01-13 2019-05-14 Baylor Research Institute Vaccines against HPV and HPV-related diseases
BR112016017764A2 (pt) 2014-02-11 2017-10-10 Massachusetts Inst Technology anticorpo antidengue de amplo espectro
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
DK3145945T3 (da) 2014-05-22 2020-09-28 Pieris Pharmaceuticals Gmbh Hidtil ukendte specifikt bindende polypeptider og anvendelser deraf
EP2955196A1 (en) 2014-06-10 2015-12-16 Effimune Antibodies directed against CD127
CA2951885C (en) 2014-06-11 2023-07-04 Kathy A. Green Use of vista agonists and antagonists to suppress or enhance humoral immunity
US20170291939A1 (en) 2014-06-25 2017-10-12 Novartis Ag Antibodies specific for il-17a fused to hyaluronan binding peptide tags
KR102659872B1 (ko) 2014-08-07 2024-04-24 노파르티스 아게 안지오포이에틴-유사 4 항체 및 사용 방법
WO2016020882A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
US10287583B2 (en) 2014-08-15 2019-05-14 Adynxx, Inc. Oligonucleotide decoys for the treatment of pain
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
EP3000814A1 (en) 2014-09-26 2016-03-30 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
EP3000483A1 (en) 2014-09-29 2016-03-30 Charité - Universitätsmedizin Berlin Means and methods for the diagnosis and treatment of neurodegenerative diseases
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
MY191428A (en) 2014-11-14 2022-06-27 Hoffmann La Roche Antigen binding molecules comprising a tnf family ligand trimer
MA41022A (fr) 2014-11-24 2017-10-03 Shire Human Genetic Therapies Ciblage lysosomial et utilisations correspondantes
JP2018505911A (ja) 2014-12-05 2018-03-01 イミュネクスト，インコーポレーテッド 推定上のｖｉｓｔａ受容体としてのｖｓｉｇ８の同定と、ｖｉｓｔａ／ｖｓｉｇ８調節剤を産生するためのその使用
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
JP6743022B2 (ja) 2014-12-24 2020-08-19 ネクシミューン インコーポレイテッド 免疫療法のためのナノ粒子組成物及び方法
WO2016120307A1 (en) 2015-01-28 2016-08-04 Pieris Ag Novel proteins specific for angiogenesis
WO2016124702A1 (en) 2015-02-06 2016-08-11 Scil Proteins Gmbh Novel egfr binding proteins
EP3064507A1 (en) 2015-03-06 2016-09-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
EP3268027B1 (en) 2015-03-13 2022-11-02 Institut National de la Santé et de la Recherche Médicale (INSERM) Hepcidin antagonists for use in the treatment of inflammation
EP4378962A3 (en) 2015-05-04 2024-07-31 Pieris Pharmaceuticals GmbH Anti-cancer fusion polypeptide
DK3292137T3 (da) 2015-05-04 2022-10-17 Pieris Pharmaceuticals Gmbh Proteiner specifikke for cd137
DK3298030T5 (en) 2015-05-18 2024-10-07 Pieris Pharmaceuticals Gmbh Anti-cancerfusionspolypeptid
KR20180008649A (ko) 2015-05-18 2018-01-24 피어이스 파마슈티컬즈 게엠베하 글리피칸-3(gpc3)에 대해 친화도를 갖는 인간 리포칼린 2의 뮤테인
TN2017000417A1 (en) 2015-06-05 2019-01-16 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
CN114805576A (zh) 2015-06-24 2022-07-29 詹森药业有限公司 抗vista抗体和片段
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
WO2017009456A1 (en) 2015-07-15 2017-01-19 Pieris Pharmaceuticals Gmbh Novel proteins specific for lag-3
KR102064396B1 (ko) 2015-07-16 2020-01-09 나피고 프로타인스 게엠베하 신규한 면역글로불린-결합 단백질 및 친화도 정제에서의 이의 용도
US10584152B2 (en) 2015-07-20 2020-03-10 Navigo Proteins Gmbh Binding proteins based on di-ubiquitin muteins and methods for generation
EP3328427B1 (en) 2015-07-27 2024-05-29 The General Hospital Corporation Antibody derivatives with conditionally enabled effector function
CA3185706A1 (en) 2015-08-03 2017-02-09 Novartis Ag Methods of treating fgf21-associated disorders
CA2994631A1 (en) 2015-08-07 2017-02-16 Pieris Pharmaceuticals Gmbh Novel fusion polypeptide specific for lag-3 and pd-1
UY36889A (es) 2015-09-09 2017-04-28 Novartis Ag Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
KR20180042433A (ko) 2015-09-09 2018-04-25 노파르티스 아게 흉선 기질 림포포이에틴 (tslp)-결합 항체 및 항체의 사용 방법
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
MY198560A (en) 2015-10-02 2023-09-05 Hoffmann La Roche Bispecific antibodies specific for a costimulatory tnf receptor
LT3356411T (lt) 2015-10-02 2021-09-10 F. Hoffmann-La Roche Ag Bispecifiniai antikūnai, specifiniai pd1 ir tim3
MX2018004157A (es) 2015-10-07 2019-04-01 F Hoffmann ­La Roche Ag Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador.
ES2994611T3 (en) 2015-10-19 2025-01-27 Cg Oncology Inc Methods of treating solid or lymphatic tumors by combination therapy
CA3003969A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
BR112018010052A2 (pt) 2015-11-19 2019-02-05 Asclepix Therapeutics Llc peptídeos com propriedades antiangiogênicas, antilinfangiogênicas e antiedêmicas e formulações de nanopartícula
SG10201911499TA (en) 2015-11-30 2020-01-30 Pieris Australia Pty Ltd Novel anti-angiogenic fusion polypeptides
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
EP3389711A1 (en) 2015-12-18 2018-10-24 Novartis AG Antibodies targeting cd32b and methods of use thereof
JP6991979B2 (ja) 2016-02-05 2022-03-04 オリオニス バイオサイエンシズ ビーブイ Ｃｄ８結合物質
BR112018016461A2 (pt) 2016-02-12 2019-10-01 Janssen Pharmaceutica Nv anticorpos e fragmentos anti-vista, usos dos mesmos e métodos de identificação dos mesmos
US11193117B2 (en) 2016-02-16 2021-12-07 Research Development Foundation Cell-targeted cytotoxic constructs
MD3423496T2 (ro) 2016-02-29 2020-01-31 Ose Immunotherapeutics Anticorpi neantagoniști direcționați împotriva lanțurilor alfa ale domeniului extracelular al receptorului IL7 și utilizarea acestora în tratamentul cancerului
US11248057B2 (en) 2016-03-07 2022-02-15 Vib Vzw CD20 binding single domain antibodies
EP3231813A1 (en) 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Trimeric costimulatory tnf family ligand-containing antigen binding molecules
WO2017175200A1 (en) 2016-04-08 2017-10-12 The Regents Of The University Of California Modified hyaluronic acid hydrogels and proteins for the time-controlled release of biologic agents
PL3443010T3 (pl) 2016-04-14 2025-02-03 Ose Immunotherapeutics NOWE PRZECIWCIAŁA ANTY-SIRPa I ICH ZASTOSOWANIA TERAPEUTYCZNE
CN117562992A (zh) 2016-04-15 2024-02-20 伊穆奈克斯特股份有限公司 抗人vista抗体及其用途
CN109071647B (zh) 2016-04-27 2022-11-22 诺华股份有限公司 抗生长分化因子15的抗体及其用途
JP2019526526A (ja) 2016-05-04 2019-09-19 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ ペプチドリンカーを含む化学的部分の部位特異的カップリングのための標的化合物
WO2017194442A1 (en) 2016-05-11 2017-11-16 F. Hoffmann-La Roche Ag Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
CA3023883A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
CN109563141A (zh) 2016-05-13 2019-04-02 奥里尼斯生物科学公司 对非细胞结构的治疗性靶向
EP3243832A1 (en) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
WO2017210598A1 (en) 2016-06-03 2017-12-07 Amgen Inc. Compositions and methods for treating an articular disorder
WO2017216724A1 (en) 2016-06-15 2017-12-21 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
EP3264092A1 (en) 2016-07-01 2018-01-03 Centogene AG Use of lyso-gb1 as druggable target
KR20230133943A (ko) 2016-08-11 2023-09-19 리플리겐 코포레이션 친화성 크로마토그래피를 위한 알칼리 안정 fc-결합 단백질
CN109963590B (zh) 2016-09-02 2024-03-15 加利福尼亚大学董事会 涉及白介素-6受体α结合单链可变片段的方法和组合物
WO2018050902A2 (en) 2016-09-15 2018-03-22 Quadrucept Bio Limited Multimers, tetramers & octamers
AU2017331739A1 (en) 2016-09-23 2019-03-07 Csl Limited Coagulation factor binding proteins and uses thereof
CN110177563A (zh) 2016-10-04 2019-08-27 阿斯克雷佩西治疗公司 用于激活tie2信号传导的化合物和方法
ES2917000T3 (es) 2016-10-24 2022-07-06 Orionis Biosciences BV Interferón-gamma mutante diana y usos del mismo
WO2018087108A1 (en) 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CA3039430A1 (en) 2016-12-19 2018-06-28 F. Hoffmann-La Roche Ag Combination therapy with targeted 4-1bb (cd137) agonists
PL3559034T3 (pl) 2016-12-20 2021-04-19 F. Hoffmann-La Roche Ag Terapia skojarzona dwuswoistymi przeciwciałami anty-CD20/anty-CD3 i agonistami 4-1BB (CD137)
KR102616666B1 (ko) 2016-12-23 2023-12-27 노파르티스 아게 인자 xi 항체 및 사용 방법
PE20191546A1 (es) 2017-01-03 2019-10-24 Hoffmann La Roche Moleculas de union antigeno biespecificas que comprenden el clon 20h4.9 anti-41bb
RU2019122482A (ru) 2017-01-18 2021-02-19 Пирис Фармасьютикалс Гмбх Мутеины липокалина с аффинностью связывания в отношении lag-3
WO2018134279A1 (en) 2017-01-18 2018-07-26 Pieris Pharmaceuticals Gmbh Novel fusion polypeptides specific for lag-3 and pd-1
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
JP7476467B2 (ja) 2017-02-06 2024-05-01 オリオンズ バイオサイエンス ビーブイ 標的化キメラタンパク質及びその使用
WO2018146074A1 (en) 2017-02-07 2018-08-16 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
WO2018146594A1 (en) 2017-02-08 2018-08-16 Novartis Ag Fgf21 mimetic antibodies and uses thereof
IL268731B1 (en) 2017-02-17 2025-03-01 Ose Immunotherapeutics New uses of anti-SIRPG antibodies
EP3589654A1 (en) 2017-03-02 2020-01-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof
US10982000B2 (en) 2017-03-24 2021-04-20 Novartis Ag Methods for treating and/or reducing the likelihood of heart failure by administering anti-activin receptor type II (anti-ActRII) antibody
JP7196094B2 (ja) 2017-03-29 2022-12-26 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 共刺激ｔｎｆ受容体のための二重特異性抗原結合分子
EP3601346A1 (en) 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
WO2018178074A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Trimeric antigen binding molecules specific for a costimulatory tnf receptor
EP3606956B1 (en) 2017-04-04 2024-07-31 F. Hoffmann-La Roche AG Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
MA49038B1 (fr) 2017-04-05 2025-01-31 F. Hoffmann-La Roche Ag Anticorps bispécifiques se liant particulièrement à pd1 et lag3
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2018234538A1 (en) 2017-06-23 2018-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) ANTAGONIST OR AGONIST OF HEPCIDINE FOR USE IN THE TREATMENT OF DYSREGULATION OF MO AND / OR MN METABOLISM
JP2020525421A (ja) 2017-06-28 2020-08-27 ノバルティス アーゲー 尿失禁を予防及び治療するための方法
EP3434692A1 (en) 2017-07-24 2019-01-30 Encefa Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases
EP3661536A4 (en) 2017-08-03 2021-07-21 Asclepix Therapeutics, Inc. PROCESSES FOR IDENTIFYING AND PREPARING PHARMACEUTICAL AGENTS TO ACTIVATE THE TIE2 RECEPTOR
EP4512469A2 (en) 2017-09-11 2025-02-26 Monash University Binding proteins to the human thrombin receptor, par4
WO2019075056A1 (en) 2017-10-10 2019-04-18 The Johns Hopkins University BIODEGRADABLE BIOMIMETIC PARTICLES
WO2019073080A1 (en) 2017-10-13 2019-04-18 Ose Immunotherapeutics ANTI-SIRPA MODIFIED ANTIBODIES AND USES THEREOF
CA3072634A1 (en) 2017-10-18 2019-04-25 Sabine Rauth Human serum albumin variants and uses thereof
EP3700933A1 (en) 2017-10-25 2020-09-02 Novartis AG Antibodies targeting cd32b and methods of use thereof
MX2020004573A (es) 2017-11-01 2020-09-25 Hoffmann La Roche Terapia de combinacion con agonistas de ox40 dirigidos.
EP3703746A1 (en) 2017-11-01 2020-09-09 F. Hoffmann-La Roche AG Novel tnf family ligand trimer-containing antigen binding molecules
MX2020004571A (es) 2017-11-01 2020-08-24 Hoffmann La Roche Contorsbodies 2+1 biespecificos.
US11414466B2 (en) 2017-11-07 2022-08-16 Navigo Proteins Gmbh Fusion proteins with specificity for ED-B and long serum half-life for diagnosis or treatment of cancer
JP2021503891A (ja) 2017-11-22 2021-02-15 ノバルティス アーゲー 抗第ＸＩ／ＸＩａ因子抗体に対する反転結合剤およびそれらの使用
KR102684627B1 (ko) 2017-11-29 2024-07-15 씨에스엘 리미티드 허혈-재관류 손상을 치료 또는 예방하는 방법
EP3502130A1 (en) 2017-12-20 2019-06-26 St. Anna Kinderkrebsforschung Ligand regulated protein-protein interaction system
JP2021506329A (ja) 2017-12-20 2021-02-22 ザンクト アンナ キンダークレプスフォルシュング リガンド制御したタンパク質−タンパク質相互作用システム
EP3502140A1 (en) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
US20200354424A1 (en) 2018-01-26 2020-11-12 Orionis Biosciences, Inc. Xcr1 binding agents and uses thereof
EP3521828A1 (en) 2018-01-31 2019-08-07 Centogene AG Method for the diagnosis of hereditary angioedema
MX2020008208A (es) 2018-02-05 2020-11-09 Orionis Biosciences Inc Agentes de unión a fibroblastos y uso de estos.
CA3092907A1 (en) 2018-03-05 2019-09-12 Klinikum Rechts Der Isar Der Technischen Universitat Munchen Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor
TWI841551B (zh) 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
CA3092002A1 (en) 2018-03-13 2019-09-19 F. Hoffmann-La Roche Ag Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies
KR20210006338A (ko) 2018-03-13 2021-01-18 오제 이뮈노테라프틱스 항-인간 SIRPa v1 항체의 이용 및 항-SIRPa v1 항체를 생산하는 방법
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CA3102607A1 (en) 2018-04-03 2019-10-10 Ose Immunotherapeutics Anti-chemokin like receptor 1 antibodies and their therapeutic applications
AU2019253232A1 (en) 2018-04-13 2020-09-03 F. Hoffmann-La Roche Ag Her2-targeting antigen binding molecules comprising 4-1BBL
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
WO2019243564A1 (en) 2018-06-21 2019-12-26 Technische Universitaet Muenchen Hepatitis b and/or hepatitis d-permissive cells and animals
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
TW202035447A (zh) 2018-07-04 2020-10-01 瑞士商赫孚孟拉羅股份公司 新穎雙特異性促效性4-1bb抗原結合分子
LT3830120T (lt) 2018-07-31 2023-07-10 Pieris Pharmaceuticals Gmbh Naujas sulietas baltymas specifinis cd137 ir pd-l1 atžvilgiu
US20230242640A1 (en) 2018-08-22 2023-08-03 Ose Immunotherapeutics ANTI-SIRPg Compounds
WO2020043683A1 (en) 2018-08-27 2020-03-05 Pieris Pharmaceuticals Gmbh Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof
CN112955468B (zh) 2018-10-01 2024-08-09 豪夫迈·罗氏有限公司 包含抗fap克隆212的双特异性抗原结合分子
JP2022511396A (ja) 2018-10-01 2022-01-31 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｃｄ４０への三価結合を伴う二重特異性抗原結合分子
WO2020078554A1 (en) * 2018-10-18 2020-04-23 Fundamental Pharma Gmbh Novel means to modulate nmda receptor-mediated toxicity
CN112867731A (zh) * 2018-10-18 2021-05-28 基本制药有限公司 调节nmda受体介导的毒性的新方法
EP3898700A1 (en) 2018-12-18 2021-10-27 Novartis AG Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
US20220025050A1 (en) 2018-12-21 2022-01-27 Ose Immunotherapeutics Bifunctional molecule directed against human pd-1
WO2020127628A1 (en) 2018-12-21 2020-06-25 F. Hoffmann-La Roche Ag Tumor-targeted superagonistic cd28 antigen binding molecules
AU2019410073B2 (en) 2018-12-21 2024-08-01 F. Hoffmann-La Roche Ag Tumor-targeted agonistic CD28 antigen binding molecules
AU2020211728A1 (en) 2019-01-23 2021-08-12 Encefa CD31 competitors and uses thereof
CN113767113B (zh) 2019-02-15 2025-01-03 因特格尔莫来库乐有限公司 密封蛋白6抗体及其用途
WO2020168024A1 (en) 2019-02-15 2020-08-20 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
CN109679963A (zh) * 2019-02-22 2019-04-26 广西医科大学 一种重组人视黄醇结合蛋白4N端19-201aa的表达与纯化方法及应用
WO2020176478A1 (en) 2019-02-25 2020-09-03 The University Of Chicago Methods and compositions for treating inflammatory and autoimmune conditions with ecm-affinity peptides linked to anti-inflammatory agents
CN113474359B (zh) 2019-02-26 2025-02-21 皮里斯制药有限公司 对cd137和gpc3特异性的新型融合蛋白
JP2022524052A (ja) 2019-03-08 2022-04-27 オックスフォード ジェネティクス リミテッド 抗体の選択方法
GB201903233D0 (en) 2019-03-08 2019-04-24 Oxford Genetics Ltd Method of selecting for antibodies
GB201903767D0 (en) 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
KR20210146999A (ko) 2019-03-29 2021-12-06 피어이스 파마슈티컬즈 게엠베하 리포칼린 뮤테인의 흡입 투여
EP3946415A1 (en) 2019-03-29 2022-02-09 Astrazeneca AB Lipocalin mutein for treatment of asthma
WO2020208049A1 (en) 2019-04-12 2020-10-15 F. Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising lipocalin muteins
WO2020247973A1 (en) 2019-06-03 2020-12-10 The University Of Chicago Methods and compositions for treating cancer with cancer-targeted adjuvants
KR20220025848A (ko) 2019-06-26 2022-03-03 에프. 호프만-라 로슈 아게 Cea 및 4-1bbl에 결합하는 항체의 융합
WO2020260326A1 (en) 2019-06-27 2020-12-30 F. Hoffmann-La Roche Ag Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
WO2021006199A1 (ja) 2019-07-05 2021-01-14 小野薬品工業株式会社 Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療
TW202120550A (zh) 2019-08-08 2021-06-01 日商小野藥品工業股份有限公司 雙特異性蛋白質
EP4025229A1 (en) 2019-09-05 2022-07-13 Klinikum rechts der Isar der Technischen Universität München Treatment of tumors by a combination of an oncolytic adenovirus, a cdk4/6 inhibitor and a further therapeutically active agent
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
EP4045044A1 (en) 2019-10-18 2022-08-24 The Regents Of The University Of California Plxdc activators and their use in the treatment of blood vessel disorders
CA3154881A1 (en) 2019-11-04 2021-05-14 Shane Olwill Her2/4-1bb bispecific fusion proteins for the treatment of cancer
EP4072682A1 (en) 2019-12-09 2022-10-19 Institut National de la Santé et de la Recherche Médicale (INSERM) Antibodies having specificity to her4 and uses thereof
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
GB202004514D0 (en) 2020-03-27 2020-05-13 Inst De Medicina Molecular Joaeo Lobo Antunes Treatment of Immunosuppressive Cancer
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
EP4149558A1 (en) 2020-05-12 2023-03-22 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
JP2023527908A (ja) 2020-06-05 2023-06-30 ピエリス ファーマシューティカルズ ゲーエムベーハー ４－１ｂｂをターゲティングする多量体免疫調節物質
PH12022553167A1 (en) 2020-06-23 2024-03-04 Hoffmann La Roche Agonistic cd28 antigen binding molecules targeting her2
JP2023531067A (ja) 2020-06-25 2023-07-20 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｃｄ３／抗ｃｄ２８二重特異性抗原結合分子
WO2022058505A1 (en) 2020-09-18 2022-03-24 Pieris Pharmaceuticals Gmbh Biomarker methods and uses
WO2022101458A1 (en) 2020-11-16 2022-05-19 F. Hoffmann-La Roche Ag Combination therapy with fap-targeted cd40 agonists
MX2023007846A (es) 2021-01-06 2023-07-07 Hoffmann La Roche Tratamiento conjunto que usa un anticuerpo biespecifico contra pd1-lag3 y un anticuerpo biespecifico de linfocitos t cd20.
US20240101673A1 (en) 2021-02-03 2024-03-28 Mozart Therapeutics, Inc. Binding agents and methods of using the same
US20240228556A9 (en) 2021-02-23 2024-07-11 Specialites Pet Food Novel canine odorant binding proteins
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers
CA3211591A1 (en) 2021-03-23 2022-09-29 Markus Zettl Her2/4-1bb bispecific fusion proteins for the treatment of cancer
WO2022200478A1 (en) 2021-03-24 2022-09-29 Pieris Pharmaceuticals Gmbh Tumor treatment with a 4-1bb/her2-bispecific agent and a her2-targeted tyrosine kinase inhibitor
AU2022255506A1 (en) 2021-04-08 2023-11-09 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
CA3214220A1 (en) 2021-04-08 2022-10-13 Marina PAVLIDOU Novel lipocalin muteins specific for connective tissue growth factor (ctgf)
WO2022243341A1 (en) 2021-05-18 2022-11-24 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding affinity for ox40
WO2022243261A1 (en) 2021-05-19 2022-11-24 F. Hoffmann-La Roche Ag Agonistic cd40 antigen binding molecules targeting cea
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
WO2023279092A2 (en) 2021-07-02 2023-01-05 Genentech, Inc. Methods and compositions for treating cancer
EP4396236A1 (en) 2021-08-30 2024-07-10 Lassen Therapeutics 1, Inc. Anti-il-11r alpha antibodies
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
WO2023089079A1 (en) 2021-11-19 2023-05-25 Pieris Pharmaceuticals Gmbh Novel fusion protein specific for ox40 and pd-l1
CR20240246A (es) 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
WO2023118497A1 (en) 2021-12-22 2023-06-29 Pieris Pharmaceuticals Gmbh Novel il-18 variants
KR20240155353A (ko) 2022-03-11 2024-10-28 인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인쎄름) B 및 t 세포의 특이적 재프로그래밍을 위한 핵산 시스템 및 이의 용도
WO2023180523A1 (en) 2022-03-24 2023-09-28 Pieris Pharmaceuticals Gmbh Process for purifying fusion proteins
CN119095880A (zh) 2022-03-28 2024-12-06 豪夫迈·罗氏有限公司 干扰素γ变体以及包含这些变体的抗原结合分子
EP4522630A1 (en) 2022-05-10 2025-03-19 Institut National de la Santé et de la Recherche Médicale Syncitin-1 fusion proteins and uses thereof for cargo delivery into target cells
KR20250025627A (ko) 2022-06-21 2025-02-24 티엠이 파마 아게 대상체의 종양을 치료하는 방법
EP4306640A1 (en) 2022-06-21 2024-01-17 TME Pharma AG Method for treating a tumor in a subject
WO2024008755A1 (en) 2022-07-04 2024-01-11 Vib Vzw Blood-cerebrospinal fluid barrier crossing antibodies
WO2024028794A1 (en) 2022-08-02 2024-02-08 Temple Therapeutics BV Methods for treating endometrial and ovarian hyperproliferative disorders
WO2024030956A2 (en) 2022-08-03 2024-02-08 Mozart Therapeutics, Inc. Cd39-specific binding agents and methods of using the same
WO2024044770A1 (en) 2022-08-26 2024-02-29 Core Biotherapeutics, Inc. Oligonucleotides for the treatment of breast cancer
WO2024052503A1 (en) 2022-09-08 2024-03-14 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to ltbp2 and uses thereof
WO2024056861A1 (en) 2022-09-15 2024-03-21 Avidicure Ip B.V. Multispecific antigen binding proteins for stimulating nk cells and use thereof
TW202428603A (zh) 2022-09-21 2024-07-16 美商思進公司 新穎的cd137及cd228特異性融合蛋白
AR130536A1 (es) 2022-09-21 2024-12-18 Seagen Inc Anticuerpos que se unen a cd228
AU2023356326A1 (en) 2022-10-06 2025-03-27 Bicara Therapeutics Inc. Multispecific proteins and related methods
GB202216503D0 (en) 2022-11-05 2022-12-21 Quadrucept Bio Ltd Non-human vertebrates & cells
WO2024118771A1 (en) 2022-11-30 2024-06-06 Integral Molecular, Inc. Antibodies directed to claudin 6, including bispecific formats thereof
TW202434642A (zh) 2023-01-06 2024-09-01 美商拉森醫療公司 用於治療甲狀腺眼病之抗ＩＬ—１１Ｒα抗體
TW202430560A (zh) 2023-01-06 2024-08-01 美商拉森醫療公司 抗ｉｌ－１８ｂｐ抗體
WO2024188965A1 (en) 2023-03-13 2024-09-19 F. Hoffmann-La Roche Ag Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
WO2024208816A1 (en) 2023-04-03 2024-10-10 Vib Vzw Blood-brain barrier crossing antibodies
WO2024243423A1 (en) 2023-05-24 2024-11-28 Mozart Therapeutics, Inc. Cd8-specific binding proteins and methods of using the same
WO2024246086A1 (en) 2023-06-01 2024-12-05 F. Hoffmann-La Roche Ag Immunostimulatory antigen binding molecules that specifically bind to bcma
WO2024246083A1 (en) 2023-06-01 2024-12-05 F. Hoffmann-La Roche Ag Bispecific antibodies targeting bcma and cd28
WO2024261013A1 (en) 2023-06-21 2024-12-26 F. Hoffmann-La Roche Ag Combination therapy with fap-targeted lymphotoxin beta receptor agonists
WO2025014774A1 (en) 2023-07-07 2025-01-16 Viridian Therapeutics, Inc. Methods of treating active and chronic thyroid eye disease
WO2025024334A1 (en) 2023-07-21 2025-01-30 Marrow Therapeutics, Inc. Hematopoietic cell targeting conjugates and related methods
WO2025050009A2 (en) 2023-09-01 2025-03-06 Children's Hospital Medical Center Identification of targets for immunotherapy in melanoma using splicing-derived neoantigens

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
AU5132096A (en) 1995-01-30 1996-08-21 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
CA2298439A1 (en) * 1997-08-06 1999-02-18 Zymogenetics, Inc. Lipocalin homologs
US6566073B1 (en) * 1998-10-19 2003-05-20 Ariad Gene Therapeutics, Inc. Materials and methods involving conditional retention domains
CA2464690A1 (en) * 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d

Also Published As

Publication number Publication date
DE59814481D1 (de) 2011-03-03
DE59805995D1 (de) 2002-11-21
US20120244596A1 (en) 2012-09-27
EP1017814B1 (de) 2002-10-16
EP1270725A1 (de) 2003-01-02
EP1017814A1 (de) 2000-07-12
DE19742706A1 (de) 1999-04-15
DK1270725T3 (da) 2011-05-02
US8536307B2 (en) 2013-09-17
DE19742706B4 (de) 2013-07-25
EP1270725B1 (de) 2011-01-19
ATE496128T1 (de) 2011-02-15
US20100285564A1 (en) 2010-11-11
US8158753B2 (en) 2012-04-17
US20060058510A1 (en) 2006-03-16
WO1999016873A1 (de) 1999-04-08
US7250297B1 (en) 2007-07-31
AU1143799A (en) 1999-04-23
US7723476B2 (en) 2010-05-25
ATE226248T1 (de) 2002-11-15

Similar Documents

Publication Publication Date Title
ATE226248T1 (de) Anticaline
DE3679017D1 (de) Komplementaere polypeptide gegen peptide oder proteine mit mindestens teilweise bekannter aminosaeure- oder nukleotidkodierender sequenz und diesbezuegliches aufbauverfahren.
PL323858A1 (en) Compounds and peptides capable to bond to a receptor of erythropoetin
PT835266E (pt) Superantigenios modificados / quimericos e seu uso
DK0436005T3 (da) Mærkede polypeptidderivater
ATE173275T1 (de) Von einem retrovirus aus der hiv-gruppe abgeleitete peptide und deren verwendung
ES2104635T3 (es) Nuevo peptido porcino con una actividad fisiologica (cnp-53).
FR2735478B1 (fr) Molecules polypeptidiques de stade pre-erythrocytaire du paludisme
ATE75231T1 (de) Neue festphasen-peptidsynthesemethoden.
CY1111763T1 (el) ΑΝΤΙΣΩΜΑΤΑ ΕΝΑΝΤΙΟΝ ΤΗΣ ΠΡΩΤΕΪΝΗΣ p51
ATE116660T1 (de) Künstliche peptid-zusammensetzungen mit immunoreaktiven antikörpern von htlv-1.
CA2021722A1 (en) Variant proteins and polypeptides possessing enhanced affinity for immobilized-metal affinity matrices
EP0412970A4 (en) Monoclonal antibodies against activated ras proteins with amino acid mutations at position 13 of the protein
DE69813476D1 (de) G-protein-gekoppelter rezeptor mit selektiver affinität für atp
PT87376A (pt) Monoklonaler antikoerper zur selektiven immunologischen bestimmung von intaktem prokollagen peptid (typ iii) und prokollagen (typ iii) in koerperfluessigkeiten
IT1241003B (it) Procedimento per la purificazione di un polipeptide ricombinante hdag equivalente, polipeptide hdag equivalente e saggi immunologici che lo utilizzano
ES2080326T3 (es) Proteinas similares a ancrod, su obtencion y empleo.
FR2710244B3 (fr) Composition diététique à base d'acides aminés essentiels.
EP1221964A4 (en) ANTIGENIC MODIFICATION OF POLYPEPTIDES
DE69032096D1 (de) Antikörper gegen das carboxy-terminale Peptid des Somatotropin-Bindungsproteins der Ratte
ATE185373T1 (de) Herstellung und anwendung von polypeptiden, die durch bindmolekuele markiert sind
ITFI920071A1 (it) Antigeni ricombinanti proteici ad aumentata immunogenicita' contenenti il peptide rappresentato dalla sequenza vqgeesndk
RU97109300A (ru) Иммуносорбент для обнаружения антител к ядерному белку вируса гепатита с в сыворотке крови
FR2710242B3 (fr) Composition énergétique à base d'acides aminés.